Zobrazeno 1 - 10
of 178
pro vyhledávání: '"E, Weck"'
Autor:
Megan C. Roberts, Kimberly S. Foss, Gail E. Henderson, Sabrina N. Powell, Katherine W. Saylor, Karen E. Weck, Laura V. Milko
Publikováno v:
Frontiers in Genetics, Vol 13 (2022)
An emerging role for DNA sequencing is to identify people at risk for an inherited cancer syndrome in order to prevent or ameliorate the manifestation of symptoms. Two cancer syndromes, Hereditary Breast and Ovarian Cancer and Lynch Syndrome meet the
Externí odkaz:
https://doaj.org/article/a19493f209134444a99bdd4bd7d6706c
Autor:
Steven M. Johnson, Daniel R. Richardson, Jonathan Galeotti, Sonia Esparza, Anqi Zhu, Yuri Fedoriw, Karen E. Weck, Matthew C. Foster, Catherine C. Coombs, Joshua F. Zeidner, Nathan D. Montgomery
Publikováno v:
HemaSphere, Vol 3, Iss 5 (2019)
Externí odkaz:
https://doaj.org/article/551ed8b5d9a34c68970a760ebccaa016
Autor:
Ezra E.W. Cohen, Roger B. Cohen, Karen E. Weck, Wendi O'Connor, Ni Zhao, Michele C. Hayward, Janelle Hoskins, Arif Sheikh, Dominic T. Moore, Ranee Mehra, Jill Gilbert, Barbara A. Murphy, Christine H. Chung, Monika K. Krzyzanowska, Tawee Tanvetyanon, Amy S. Lucas, D. Neil Hayes
CCR Translation for This Article from Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30945b66f00a71a691eadb90c6a3c928
https://doi.org/10.1158/1078-0432.22443099.v1
https://doi.org/10.1158/1078-0432.22443099.v1
Autor:
Ezra E.W. Cohen, Roger B. Cohen, Karen E. Weck, Wendi O'Connor, Ni Zhao, Michele C. Hayward, Janelle Hoskins, Arif Sheikh, Dominic T. Moore, Ranee Mehra, Jill Gilbert, Barbara A. Murphy, Christine H. Chung, Monika K. Krzyzanowska, Tawee Tanvetyanon, Amy S. Lucas, D. Neil Hayes
Purpose: A multicenter, open-label, phase II trial was conducted to evaluate the efficacy, safety, and tolerability of selumetinib in iodine-refractory papillary thyroid cancer (IRPTC).Experimental Design: Patients with advanced IRPTC with or without
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9be17fc302e2876868f19cf9275a53cd
https://doi.org/10.1158/1078-0432.c.6519675
https://doi.org/10.1158/1078-0432.c.6519675
Autor:
Victoria M. Pratt, Larisa H. Cavallari, Makenzie L. Fulmer, Andrea Gaedigk, Houda Hachad, Yuan Ji, Lisa V. Kalman, Reynold C. Ly, Ann M. Moyer, Stuart A. Scott, R.H.N. van Schaik, Michelle Whirl-Carrillo, Karen E. Weck
Publikováno v:
The Journal of molecular diagnostics : JMD, 24(10), 1051-1063. Elsevier Inc.
The goals of the Association for Molecular Pathology Clinical Practice Committee's Pharmacogenomics (PGx) Working Group are to define the key attributes of pharmacogenetic alleles recommended for clinical testing and a minimum set of variants that sh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::266e61f6e073bae1c479a3a9fcefe7a2
https://pure.eur.nl/en/publications/0c57d93a-8856-4864-afdf-283c0a8c7453
https://pure.eur.nl/en/publications/0c57d93a-8856-4864-afdf-283c0a8c7453
Autor:
Michelle Whirl-Carrillo, Reynold C. Ly, R.H.N. van Schaik, Ann M. Moyer, Andrea Gaedigk, Lisa V. Kalman, Andria L. Del Tredici, Stuart A. Scott, Larisa H. Cavallari, Houda Hachad, Yuan Ji, Victoria M. Pratt, Karen E. Weck
Publikováno v:
The Journal of Molecular Diagnostics. 23:1047-1064
The goals of the Association for Molecular Pathology Clinical Practice Committee's Pharmacogenomics (PGx) Working Group are to define the key attributes of pharmacogenetic alleles recommended for clinical testing, and to determine a minimal set of va
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::91cb1d930037b0edb0b5d4a902a61025
https://doi.org/10.1016/j.jmoldx.2021.05.013
https://doi.org/10.1016/j.jmoldx.2021.05.013
Autor:
Yiqing Chen, Larisa H. Cavallari, Francesco Franchi, Craig R. Lee, Sony Tuteja, Philip E. Empey, Amber L. Beitelshees, Jay Giri, Caitrin W. McDonough, Rolf P. Kreutz, Kelsey J. Cook, Julie A. Johnson, James M. Stevenson, Nita A. Limdi, Julio D. Duarte, Karen E. Weck, Chrisly Dillon, James C. Lee, James C. Coons, Dominick J. Angiolillo, Todd C. Skaar, Yan Gong, Cameron D. Thomas, George A. Stouffer
Publikováno v:
Clin Pharmacol Ther
Genotyping for CYP2C19 no function alleles to guide antiplatelet therapy after percutaneous coronary intervention (PCI) improves clinical outcomes. Although results for the increased function CYP2C19*17 allele are also reported, its clinical relevanc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df759aaa2959187bddcecceabd929eec
https://doi.org/10.1002/cpt.2039
https://doi.org/10.1002/cpt.2039
Autor:
Michelle Whirl-Carrillo, Stuart A. Scott, Larisa H. Cavallari, Karen E. Weck, Ann M. Moyer, Yuan Ji, Victoria M. Pratt, Lisa V. Kalman, Andria L. Del Tredici, Reynold C. Ly, Houda Hachad
Publikováno v:
The Journal of Molecular Diagnostics. 22:847-859
The goal of the Association for Molecular Pathology (AMP) Clinical Practice Committee's AMP Pharmacogenomics (PGx) Working Group is to define the key attributes of PGx alleles recommended for clinical testing and a minimum set of variants that should
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::54023a14bac193458aed914779d89777
https://doi.org/10.1016/j.jmoldx.2020.04.204
https://doi.org/10.1016/j.jmoldx.2020.04.204
Autor:
Margaret Waltz, Kristine J. Kuczynski, Karen E. Weck, Gail E. Henderson, Rita M. Butterfield, Teresa Edwards, R. Jean Cadigan, Jonathan S. Berg, Christine Rini, Molly Ewing
Publikováno v:
European Journal of Human Genetics
To realize the promise of population genomic screening for rare medically actionable conditions, critical challenges in the return of normal/negative results must be understood and overcome. Our study objective was to assess the functioning of a new
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69f17948b25a61d86cee0ea03a5aabed
https://doi.org/10.1038/s41431-020-0657-1
https://doi.org/10.1038/s41431-020-0657-1
Autor:
Kristin R. Muessig, Margaret Waltz, Gail E. Henderson, Jonathan S. Berg, R. Jean Cadigan, Karen M. Meagher, Karen E. Weck, Katrina A.B. Goddard
Publikováno v:
Personalized Medicine
Aim: Before population screening of ‘healthy’ individuals is widely adopted, it is important to consider the harms and benefits of receiving positive results and how harms and benefits may differ by age. Subjects & methods: Participants in a prev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7168d9bb72f9e66d63f5dd2efe9671b1
https://doi.org/10.2217/pme-2019-0067
https://doi.org/10.2217/pme-2019-0067